LNP formulations produce strong immune responses, data shows
Drug Discovery World
FEBRUARY 15, 2024
Hypothetically, any mRNA-based drug using S-Ac7-DOG as the lipid base would therefore have improved efficacy and a better safety profile.
Immune Response Treatment Vaccine 
Study proves value of infection studies in developing new vaccines
Drug Discovery World
MAY 2, 2024
A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The data from this COVCHIM01 study showed durable immunity post-infection/vaccination against the original Covid-19 virus.
Vaccine 
147
147 Join 42,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
“Game-changing” personalised cancer vaccine enters UK clinical trials
Drug Discovery World
APRIL 26, 2024
A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. in the combination arm and 62.2% in the combination arm and 62.2%
Clinical Trials 130
130 
Chinese regulator approves personalised cancer vaccine trial
Drug Discovery World
MARCH 30, 2023
Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.
Vaccine 130
130 
Immuno-oncology innovations redefining cancer treatment in 2024
Drug Target Review
JANUARY 23, 2024
What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.
Treatment 122
122 
Personalised mRNA cancer vaccine prolongs survival in melanoma
Drug Discovery World
APRIL 16, 2023
Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%
Vaccine 130
130 
Plant-based squalene alternative suitable for vaccine use
Drug Discovery World
DECEMBER 8, 2022
Evonik has launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. Adjuvants are additives that boost the body’s immune response to the active ingredient in a vaccine. It is alarming that biodiversity across our planet is declining at a rapid rate.
Vaccine 130
130 
Merck and Moderna to jointly develop personalised cancer vaccine
Drug Discovery World
NOVEMBER 8, 2022
Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).
Vaccine 130
130 
HIV combination regimen could lead to viral remission
Drug Discovery World
FEBRUARY 24, 2023
AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The trial also evaluated the efficacy of HTI vaccines in combination with VES to avoid, delay or contain viral rebound compared to a placebo group.
Immune Response 130
130 
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
The Pharma Data
AUGUST 16, 2021
The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.
Recombinant polyclonal drug trial for HBV gets FDA green light
Drug Discovery World
AUGUST 7, 2024
The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. It is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection.
Drug Trials 147
147 
Could a modified cold sore virus cure brain cancer?
Drug Discovery World
MAY 23, 2024
A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The research team has already used the virus in a small Phase I trial where responses to the treatment were seen in 11 out of 12 children.
Virus 147
147 
Transforming cancer treatment for greatest impact
Drug Target Review
JANUARY 15, 2024
Research 1 has shown that neutrophil elastase selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilises adaptive immunity, and avoids resistance mechanisms. Could you provide insights into the driving factors behind exploring novel treatments for cancer types?
Treatment 105
105 
FDA approves Covid-19 mAb for emergency use in immunocompromised
Drug Discovery World
MARCH 26, 2024
It is approved in adults and adolescents (12 years of age and older weighing at least 40kg) who are moderate-to-severely immune compromised due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to Covid-19 vaccination.
FDA Approval 130
130 
Malfunctioning monocytes could be drug target in Long Covid
Drug Discovery World
MARCH 17, 2023
Researchers have shown for the first time that malfunctioning behaviour of a type of immune cell is linked to specific symptoms of Long Covid. Normally functioning monocytes, made in the bone marrow, would travel through the blood to the lungs where they surround and kill the virus and boost the immune response.
Immune Response 130
130 
BioNTech to deliver prestigious lecture on mRNA
Drug Discovery World
JULY 26, 2022
Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The first half of the lecture, titled ‘mRNA Cancer Vaccines’ will be delivered by U?ur The lecture will be delivered in two halves by U?ur
Vaccine 130
130 
mRNA Cancer Vaccines and Therapies: An Overview
Advarra
JANUARY 11, 2024
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.
Vaccine 52
52 
Insights into cellular therapies for cancer treatment
Drug Target Review
FEBRUARY 21, 2024
Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” This involves the use of CAR-T cell products derived from donor T cells, hence the term “off the shelf,” making it easier to standardise treatments.
Therapies 64
64 
The future of cancer immunotherapy with Elicio Therapeutics
Drug Target Review
MARCH 1, 2024
How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.
Immune Response 105
105 
Moderna says its COVID-19 vaccine shows promise in elderly patients
The Pharma Data
AUGUST 27, 2020
Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . The company has already tested the treatment on 10 adults between the ages of 56-70, and 10 over 71. Conor Kavanagh. Source link.
Vaccine 90
90 
Accelerated development for Covid-19 monoclonal antibody
Drug Discovery World
JANUARY 3, 2023
While vaccines remain the cornerstone of active immunisation, vulnerable populations that cannot build an immune response with vaccination can benefit from protection from a monoclonal antibody.” .
Immune Response 130
130 
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
The Pharma Data
APRIL 15, 2022
NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About Pfizer: Breakthroughs That Change Patients’ Lives.
Where is the Ignite Theater tech leading us?
Drug Discovery World
JANUARY 22, 2024
In 2023, SandboxAQ announced a bio-pharma molecular simulation division, AQBioSim, to help biopharma and research institutions make treatment breakthroughs for patients. The company’s technology includes crypto-agile security, quantum sensing, and quantum simulation and optimisation.
Immune Response 147
147 
Revealed: How Covid-19 variants stay ahead of immune defences
Drug Discovery World
JANUARY 17, 2024
5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL). The study examined viral evolution in eight Omicron variants to better understand how the virus has reacted since the introduction of vaccinations.
Virus 130
130 
Janssen's lead coronavirus vaccine shows preclinical promise
The Pharma Data
SEPTEMBER 4, 2020
The findings have validated confidence in the experimental vaccine, the firm noted. Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, The company also announced the end of development of pimodivir, an investigational antiviral treatment for influenza A infection. Source link.
Vaccine 52
52 
Immunotherapy is here to stay
Drug Discovery World
JULY 25, 2023
These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. It was, at the time, a very small dosing – a few micrograms combined with an antigen, in other words, an adjuvant to a therapeutic vaccine.
Immune Response 246
246 
Leishmania species: A narrative review on surface proteins with structural aspects involved in host–pathogen interaction
Chemical Biology and Drug Design
APRIL 28, 2023
Leishmania infection may arise from virulence factors; they are treatable with medications or vaccinations more promptly and might greatly shorten the duration of treatment.
Immune Response 100
100 
New antiviral offers potential solution to resistant Covid-19 variants
Drug Discovery World
AUGUST 10, 2023
COV-X targets the key coronavirus PLpro enzyme, which is essential for viral replication and evasion of host immune response. COV-X also demonstrated a superior drug metabolism and pharmacokinetics (DMPK) profile to nirmatrelvir.
Immune Response 130
130 
Sanofi and GSK initiate new Phase 2 protein-based COVID-19 vaccine candidate
The Pharma Data
FEBRUARY 22, 2021
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate. New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. In parallel, development work on new SARS-CoV-2 variants underway.
Vaccine 52
52 
Therapeutic Vaccine Is Keeping Melanoma in Remission 4 Years On
The Pharma Data
JANUARY 25, 2021
25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan.
Vaccine 52
52 
Allergists’ Group Updates Guidelines on COVID-19 Vaccines
The Pharma Data
DECEMBER 22, 2020
22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. per 1 million doses given to patients, according to the ACAAI.
Vaccine 52
52 
COADMINISTRATION OF ITS 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
The Pharma Data
JUNE 24, 2021
The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines. Pfizer-BioNTech COVID-19 Vaccine booster plus placebo. 20vPnC plus placebo.
Vaccine 52
52 
2023 cancer research highlights: Drug development at its best
Drug Discovery World
FEBRUARY 28, 2024
According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG. Research into new cancer drugs remain strong.
Drug Development 162
162 
New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
The Pharma Data
OCTOBER 14, 2021
Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,
Vaccine 52
52 
ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies
The Pharma Data
DECEMBER 18, 2020
ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. The ACAAI COVID-19 Vaccine Task Force issued the guidance related to the risk for an allergic reaction with the Pfizer-BioNTech COVID-19 vaccine that was given emergency use authorization by the U.S. Professional. FRIDAY, Dec. FRIDAY, Dec.
Vaccine 52
52 
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
The Pharma Data
JUNE 17, 2022
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.
Vaccine 52
52 
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
The Pharma Data
MARCH 11, 2021
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.
This week in drug discovery (13-17 March)
Drug Discovery World
MARCH 17, 2023
In the news this week we have covered a number of early-stage studies that could lead to potentially huge breakthroughs in the treatment of metastatic breast cancer, Long Covid, bacterial diseases, bone cancer, and autoimmune conditions. The top stories: mRNA vaccine 100% effective against deadly bacteria For the first time, researchers have (..)
Vaccine 130
130 
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
The Pharma Data
FEBRUARY 23, 2022
* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.
Vaccine 52
52 
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
The Pharma Data
DECEMBER 10, 2020
–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(
Vaccine 52
52 
Women in STEM with Delphine Guyon-Gellin
Drug Target Review
MARCH 26, 2024
DGG: At Osivax, we’re working on a new class of vaccines that target invariant parts of mutating viruses; this approach is disruptive and very different from conventional vaccines. DGG: Vaccines are experiencing a revolution in the post-COVID era with the emergence of mRNA technology.
Vaccine 110
110 
U.S. FDA APPROVES TICOVAC™, PFIZER’S TICK-BORNE ENCEPHALITIS (TBE) VACCINE
The Pharma Data
AUGUST 15, 2021
Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 1 TICOVAC is the only FDA-approved vaccine to help protect U.S. We are proud to deliver the first vaccine to help protect people in the U.S.
FDA Approval 52
52 
FIRST AUTHORIZATION IN EUROPEAN UNION FOR COVID-19 VACCINE IN ADOLESCENTS
The Pharma Data
JUNE 24, 2021
This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. COMIRNATY was the first COVID-19 vaccine to receive authorization in the EU and is the first to have its CMA extended to adolescents. g doses of the COVID-19 vaccine.
Vaccine 52
52 
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
The Pharma Data
JULY 23, 2021
government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. government with 500 million doses of the companies’ COVID-19 vaccine for donation to the world’s poorest nations. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country.
Vaccine 52
52 
Let's personalize your content